Some analysts put the timeline closer to 2028 to 2029 for Australian market availability, depending on how quickly phase 3 data comes in and how fast the TGA review process moves
SheMed's clinical team can help you review your options
p = 0.007), total hip (ETD: -0.020 g/cm
Description Description Retatrutide Multi-Dose Pen Retatrutide is a synthetic peptide currently being studied in laboratory and research settings for its interaction with GLP-1, GIP, and glucagon receptors
Compounded options may be available, but they are not FDA-approved and should be approached carefully
These may include blood sugar markers, insulin resistance markers, thyroid function, liver enzymes, kidney function, cholesterol, triglycerides, inflammation markers, hormone-related testing, or nutrient status when appropriate